Subscribe

Straumann Holding AG (STMN.SW)

CHF103.90 -2.10 (-1.98%)
CH SIX Healthcare Medical - Instruments & Supplies
Address Peter Merian-Weg 12 4002
Basel, CH
CEO Guillaume Daniellot
Website straumann.com
IPO 1998-07-17
ISIN CH1175448666

Explore sections of this company profile

Also trades on London Stock Exchange · 0QMV.L (CHF) Other OTC · SAUHF (USD) Other OTC · SAUHY (USD) Swiss Exchange · STMN.SW (CHF)
Description

Straumann Holding AG is a global leader in providing advanced solutions for tooth replacement and orthodontic treatment. The company actively researches, develops, manufactures, and distributes a comprehensive range of dental products and services designed for tooth correction, restoration, replacement, and the prevention of tooth loss. Its extensive portfolio includes various dental implant systems (such as titanium, titanium alloy, ceramic, and mini implants), specialized surgical instruments, sophisticated CAD/CAM prosthetics, and the Clear Correct orthodontic aligners. Straumann also supplies vital biomaterials, including bone substitutes, membranes, and biologics, alongside cutting-edge digital tools like intraoral scanners, 3D printers, and milling machines for dental professionals and laboratories. Additionally, the company offers educational and training services to its customers. Straumann serves a diverse clientele, encompassing general dentists, specialists, dental technicians, laboratories, and institutional clients such as distributors, hospitals, and universities, reaching approximately 100 countries through its broad network of subsidiaries and partners. Established in 1954, Straumann Holding AG is headquartered in Basel, Switzerland.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CHF103.90 -2.10 (-1.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
408.5K
Beta
1.39
Float Shares
107.92M
Free Float %
67.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.77% -3.11% -2.29% -14.89% -18.65% -12.09% -27.38% -41.89% -37.55% +123.27% +4,151.28%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Buy
Price Targets & DCF
Current price
103.90
DCF (Unlevered) 24.77 -76.2%
DCF (Levered) 29.43 -71.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 55% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 7 0
Hold 7 0
Sell 2 0
Strong Sell 0 0
Quality scores
Altman Z-Score
9.14
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +4.0% Q4'25: +5.2% (vs Q4'23)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -8.2% Q4'25: +204.0% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +15.9% Q4'25: +16.0% (vs Q4'23)
  • ✓
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +21.1% ★ Q4'25: +65.1% (vs Q4'23)
  • ✓
    ROIC Medical - Instruments & Supplies: +6.0%
    +23.6% ★
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +0.2% Q4'25: -0.7% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    1.19× Q4'25: 0.20× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.38) × ERP
WACC = 95% × Ke + 5% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 24.60 Current price: 103.90
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
16 Rev. Ana.
15 EPS Ana. 		Dec 2027
15 Rev. Ana.
14 EPS Ana. 		Dec 2028
13 Rev. Ana.
11 EPS Ana. 		Dec 2029
12 Rev. Ana.
4 EPS Ana. 		Dec 2030
6 Rev. Ana.
4 EPS Ana.
Revenue
693.58M
est: 705.06M (-1.6%)
686.25M
est: 705.24M (-2.7%)
679.92M
est: 688.90M (-1.3%)
710.27M
est: 714.14M (-0.5%)
798.60M
est: 794.14M (+0.6%)
917.52M
est: 916.26M (+0.1%)
1.11B
est: 1.10B (+1.2%)
1.36B
est: 1.35B (+1.0%)
1.60B
est: 1.59B (+0.3%)
1.43B
est: 1.42B (+0.5%)
2.02B
est: 2.02B (+0.2%)
2.32B
est: 2.32B (+0.1%)
2.41B
est: 2.54B (-5.1%)
2.50B
est: 2.50B (+0.3%)
2.61B
est: 2.59B (+0.5%)
2.74B
2.68B – 2.78B
+5.8% YoY
3.01B
2.93B – 3.12B
+9.8% YoY
3.31B
3.31B – 3.31B
+9.9% YoY
3.65B
3.56B – 3.74B
+10.4% YoY
4.05B
3.95B – 4.15B
+10.9% YoY
EBITDA
114.94M
est: 219.99M (-47.8%)
93.57M
est: 118.51M (-21.0%)
140.43M
est: 83.52M (+68.1%)
175.69M
est: 160.78M (+9.3%)
218.05M
est: 264.12M (-17.4%)
258.86M
est: 624.9K (+41,324.1%)
323.18M
est: 298.14M (+8.4%)
403.73M
est: 402.46M (+0.3%)
479.20M
est: 419.58M (+14.2%)
230.45M
est: 378.45M (-39.1%)
591.48M
est: 476.25M (+24.2%)
678.33M
est: 522.18M (+29.9%)
495.42M
est: 656.13M (-24.5%)
726.15M
est: 654.38M (+11.0%)
549.00M
est: 669.27M (-18.0%)
707.91M
692.58M – 717.15M
+5.8% YoY
777.48M
755.31M – 804.39M
+9.8% YoY
854.10M
853.76M – 854.44M
+9.9% YoY
943.35M
919.53M – 966.30M
+10.4% YoY
1.05B
1.02B – 1.07B
+10.9% YoY
EBIT
78.02M
est: 154.40M (-49.5%)
58.67M
est: 80.59M (-27.2%)
114.93M
est: 59.59M (+92.9%)
181.76M
est: 119.97M (+51.5%)
185.09M
est: 167.36M (+10.6%)
226.85M
est: 223.32M (+1.6%)
329.11M
est: 271.69M (+21.1%)
335.15M
est: 442.44M (-24.2%)
383.09M
est: 409.65M (-6.5%)
129.53M
est: 346.07M (-62.6%)
494.42M
est: 435.49M (+13.5%)
515.62M
est: 477.49M (+8.0%)
372.64M
est: 539.26M (-30.9%)
581.22M
est: 530.96M (+9.5%)
549.00M
est: 550.07M (-0.2%)
581.82M
569.22M – 589.41M
+5.8% YoY
639.00M
620.78M – 661.11M
+9.8% YoY
701.97M
701.69M – 702.25M
+9.9% YoY
775.33M
755.75M – 794.18M
+10.4% YoY
860.13M
838.41M – 881.05M
+10.9% YoY
Net Income
70.95M
est: 123.20M (-42.4%)
36.44M
est: 71.61M (-49.1%)
101.20M
est: 35.56M (+184.6%)
157.83M
est: 104.84M (+50.5%)
70.68M
est: 178.09M (-60.3%)
229.60M
est: 81.34M (+182.3%)
272.92M
est: 274.59M (-0.6%)
272.77M
est: 345.42M (-21.0%)
306.47M
est: 322.90M (-5.1%)
91.28M
est: 269.70M (-66.2%)
396.08M
est: 339.40M (+16.7%)
434.79M
est: 375.16M (+15.9%)
246.07M
est: 287.88M (-14.5%)
388.32M
est: 502.75M (-22.8%)
358.00M
est: 493.56M (-27.5%)
478.94M
414.99M – 541.71M
-3.0% YoY
564.97M
531.30M – 647.72M
+18.0% YoY
648.13M
614.55M – 755.58M
+14.7% YoY
738.26M
714.02M – 761.60M
+13.9% YoY
849.52M
821.63M – 876.38M
+15.1% YoY
SGA
412.27M
est: 361.90M (+13.9%)
423.61M
est: 415.84M (+1.9%)
423.57M
est: 413.79M (+2.4%)
413.00M
est: 438.12M (-5.7%)
445.01M
est: 465.54M (-4.4%)
494.07M
est: 511.57M (-3.4%)
560.90M
est: 590.47M (-5.0%)
680.31M
est: 692.64M (-1.8%)
800.14M
est: 805.02M (-0.6%)
730.68M
est: 702.12M (+4.1%)
1.00B
est: 883.56M (+13.6%)
1.22B
est: 968.76M (+26.4%)
1.38B
est: 1.05B (+31.1%)
1.20B
est: 1.13B (+5.6%)
—
est: 1.08B (-100.0%)
1.14B
1.11B – 1.15B
+5.8% YoY
1.25B
1.21B – 1.29B
+9.8% YoY
1.37B
1.37B – 1.37B
+9.9% YoY
1.52B
1.48B – 1.55B
+10.4% YoY
1.68B
1.64B – 1.72B
+10.9% YoY
EPS
0.45
est: 6.94 (-93.5%)
0.24
est: 5.35 (-95.5%)
0.65
est: 7.23 (-91.0%)
1.01
est: 8.81 (-88.5%)
0.45
est: 0.86 (-47.6%)
1.47
est: 1.24 (+19.0%)
1.80
est: 1.58 (+14.0%)
1.72
est: 1.79 (-4.1%)
1.93
est: 2.15 (-10.2%)
0.57
est: 1.54 (-63.0%)
2.49
est: 2.70 (-7.7%)
2.73
est: 3.09 (-11.7%)
1.54
est: 1.81 (-14.7%)
2.44
est: 3.15 (-22.5%)
2.24
est: 3.05 (-26.7%)
3.07
2.60 – 3.39
+0.4% YoY
3.65
3.32 – 4.05
+18.8% YoY
4.17
3.85 – 4.73
+14.4% YoY
4.62
4.47 – 4.77
+10.8% YoY
5.32
5.14 – 5.48
+15.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B 3/5 3/5 5/5 5/5 2/5 1/5 1/5
2026-05-08 B 3/5 3/5 4/5 5/5 2/5 1/5 1/5
2026-05-07 B 3/5 3/5 4/5 5/5 2/5 1/5 1/5
2026-05-06 B 3/5 3/5 4/5 5/5 2/5 1/5 1/5
2026-05-05 B 3/5 3/5 4/5 5/5 2/5 2/5 1/5
2026-05-04 B 3/5 3/5 4/5 5/5 2/5 2/5 1/5
2026-04-30 B 3/5 3/5 4/5 5/5 2/5 2/5 1/5
2026-04-29 B 3/5 3/5 4/5 5/5 2/5 2/5 1/5
2026-04-28 B 3/5 3/5 4/5 5/5 2/5 2/5 1/5
2026-04-27 B 3/5 3/5 4/5 5/5 1/5 2/5 1/5
2026-04-24 B 3/5 3/5 4/5 5/5 1/5 2/5 1/5
2026-04-23 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-22 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-21 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-20 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-17 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-16 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5
2026-04-15 B- 3/5 3/5 4/5 5/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
800.50M
OE per share TTM
5.03
Owner's Yield
6.06%
Maintenance CapEx ratio
54.70%
Maint CapEx / Avg PPE
30.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
48.4K
Shares Outstanding
159.45M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Guillaume Daniellot Chief Executive Officer, Interim Head of Dental Service Organizations & Member of Executive Management Board 4M male
Andreas Utz Head of Implantology Business Unit (IBU) and Member of Executive Management Board — male
Florian Kirsch Head of Integrated Dental Technologies & Member of Management Board — male
Grant Bester Regional Head of North America & Member of the Executive Management Board — male
Holger Haderer Regional Head of Europe, Middle East & Africa and Member of Executive Management Board — male
Isabelle Wege Chief Financial Officer & Member of Executive Management Board — female
Kok-Kien Loh Regional Head Asia Pacific & Member of the Executive Management Board — male
Sara Dalmasso Head of the Dental Service Organization (DSO) and Member of Executive Management Board — female
Sébastien Roche Chief Operations & Supply Chain Officer and Member of Executive Management Board — male
Alexei Costa Executive Vice President of Latin America, President Neodent & Member of Executive Management Board — male
Thomas Friese Chief Technology & Information Officer and Member of Executive Management Board — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies